Rising Prevalence Of Chronic Diseases Propelling Growth In Branded Generics Market Is Supporting Development Across The Branded Generics Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The Branded Generics Market By 2030 Based On Its 2026 Value?

The branded generics market has experienced substantial growth in recent years. Its value is anticipated to climb from $393.5 billion in 2025 to $434.56 billion in 2026, at a compound annual growth rate (CAGR) of 10.4%. This past expansion can be attributed to factors such as the expiration of patents for key drugs, increasing acceptance of generic medications, rising healthcare spending, government support for generics, and the growing prevalence of chronic diseases.

The branded generics market is anticipated to experience substantial expansion in the coming years. Its value is projected to reach $653.17 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.7%. This projected growth during the forecast period is primarily attributable to several factors, including the expanding range of branded generics, the increased integration of digital marketing within the pharmaceutical sector, a rise in collaborations with healthcare providers, the development of emerging markets, and continuous improvements in drug formulation technologies. Key trends anticipated over this period encompass a heightened awareness of brands among patients, the implementation of differentiated marketing approaches, an increase in the volume of prescriptions for branded generics, a growing inclination among physicians to prescribe branded generics, and the ongoing expansion of emerging markets for generic drugs.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

Which Growth Drivers Are Expected To Support The Branded Generics Market Forward?

The rising incidence of chronic diseases is anticipated to fuel the expansion of the branded generics market. Chronic diseases are persistent health conditions that are often incurable but manageable and controllable. Their increase stems from factors such as heightened tobacco use, insufficient nutrition, sedentary lifestyles, and excessive alcohol consumption, among others. Globally, consumers are favoring branded generics for managing chronic diseases due to their affordability compared to conventional medications. For instance, in April 2025, data from the Centers for Disease Control and Prevention, a US-based federal agency, indicated that in 2023, approximately 76.4% of U.S. adults reported experiencing at least one of 12 selected chronic conditions, with 51.4% of U.S. adults reporting multiple chronic conditions. Therefore, the growing prevalence of chronic diseases is a significant driver for the branded generics market’s growth.

How Is The Branded Generics Market Distributed Across Key Segments?

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

Which Trends Are Expected To Shape The Branded Generics Market?

Major companies in branded generics are establishing partnerships with relevant firms to pool resources and penetrate new markets. For instance, in September 2024, Biocon Ltd., an India-based pharmaceutical company, formed a partnership with Tabuk Pharmaceuticals. Biocon will be responsible for the development and manufacturing of the GLP-1 products, ensuring high-quality biopharmaceuticals crafted for diabetes treatment. Tabuk Pharmaceuticals will hold the marketing authorization rights and manage the registration, importation, and promotion of these products across the Middle East, particularly in Saudi Arabia. The agreement includes provisions for future expansion into other GLP products beyond the initial offerings, allowing for a broader spectrum of diabetes treatments. The partnership aims to deliver unique health solutions that enhance the well-being of patients in Saudi Arabia and surrounding areas, aligning with both companies’ commitment to improving healthcare access. Tabuk Pharmaceuticals is a Saudi Arabia-based pharmaceutical company that markets both branded and generic pharmaceutical products.

Which Organizations Are Involved In The Branded Generics Market?

Major companies operating in the branded generics market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

Access The Complete Branded Generics Market Report:

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Which Region Accounts For The Highest Share Of The Branded Generics Market?

North America was the largest region in the branded generics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Branded Generics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

Browse Through More Reports Similar to the Global Branded Generics Market 2026, By The Business Research Company

Branded Generics Market Report 2026

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Specialty Generics Market Report 2026

https://www.thebusinessresearchcompany.com/report/specialty-generics-global-market-report

Specialty Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/specialty-products-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795